Rentiapril (SA-446) is an angiotensin-converting-enzyme (ACE) inhibitor that has antihypertensive activity. This compound binds to ACE and blocks the conversion of angtiotensin I to angtiontensin II. Angiotensin II has vasoconstrictive activity, which rentiapril prevents, leading to vasodilation. Rentiapril has been shown to inhibit ADE activity more strongly and for longer periods than two other ACE inhibitors (captopril, and alacepril), and reduces blood pressure more quickly and for a longer time in patients with renovascular hypertension. Because rentiapril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, it increases sodium excretion and (subsequently) water outflow.

Clonixeril is a glyceryl ester of a nonsteroid anti-inflammatory drug clonixin, developed by Scherico Ltd in the 1970s. Oral administration of clonixeril delays the onset of castor oil-induced diarrhoea in rats.

ISOTIQUIMIDE is an anti-ulcerative agent.

Biclotymol, a phenolic antiseptic has multiple actions: it has bacteriostatic, bactericidal, anti-inflammatory and analgesic activity. Biclotymol is recommended as a prompt, effective and safe first-line option for the treatment of sore throat.

Nicametate is a vasodilator, which enhances blood flow and oxygen to the brain, aids stroke recovery. It also can use for treating intermittent claudication in certain patients.

Morsuximide is succinimide derivative patented by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt. as an antiepileptic agent. In cats, Morsuximide had mild hypnotic effects when given i.p., and the status epileptic induced by Tetracor was brought under control. Tetracor, given after the administration of Morsuximide, caused only subconvulsive seizures in cats accompanied by an occasional jerk of the skeletal musculature. When 16 epileptic patients were treated with oral Morsuximide (1.0-2.0 g. daily for an av. of 42 days) the drug produced a favorable effect in all forms of human epilepsy, particularly in cases of psychomotor attacks, atypical forms, and petit mal. The major type of epilepsy (grand mal) did not respond to the drug therapy as markedly as the other forms, although drug caused some improvement in these cases.

The organophosphate compound Naftalofos is an anthelmintic drug. In Australia it is approved for veterinary use. Naftalofos has been used for many years to control nematodes of livestock. Naftalofos boluses are used against nematodes of cattle. Naphthalophos (36.6 to 51.2 mg/kg) was also 93% efficient against the multiple resistant strains of Trichostrongylus colubriformis in sheep. Naphthalophos showed efficacy against Haemonchus contortus (> 99 %),Trichostrongylus axei (99.3 %), Teladorsagia circumcincta (97.8 %), Trichostrongylus colubriformis (99.2 %), Cooperia punctata/curticei/pectinata (90.4 %), Nematodirus spathiger (89.2 %) and Oesophagostomum venulosum/columbianum (93.7 %). Naphthalophos represents an effective therapeutic alternative for incorporation into worm control programmes.

Pomisartan, also known as BIBR-363, is an angiotensin type 1 receptor antagonist. It was investigated for the treatment of Congestive heart failure and hypertension. However, no development reports available at this moment.

Palosuran, also known as ACT-058362, a potent and specific antagonist of the human UT receptor. Urotensin inhibition with palosuran was a promising alternative in pulmonary arterial hypertension. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Palosuran improves pancreatic and renal function in diabetic rats. Phase-II clinical trials for diabetic nephropathies and cardiovascular disorders were discontinued.

Levemopamil is a novel compound of the phenylalkylamine class of calcium channel blockers, possesses exceptionally high blood-brain barrier penetrability characteristics. It has a potent antagonistic action on serotonin 5-HT2-receptors. Activation of these receptors stimulates inositol phospholipid hydrolysis that can lead to the release of Ca2+ from intracellular stores as well as protein kinase C activation. Levemopamil thus has the potential for blocking deleterious increases of intracellular calcium arising from both intracellular stores and from the extracellular space. Levemopamil reduce both infarct size and extent of neuronal injury following permanent focal or transient global ischemia. The acute effect of bilateral clamping of carotid arteries on local cerebral blood flow was measured in the presence and absence of levemopamil in a separate group of rats. The data suggest that pretreatment with levemopamil reduces impairment in spatial behaviour and that this effect seems not related to the compound's cerebral vasodilatory action, but to direct neuronal mechanisms.